Welcome to the international HTA database

Showing [23369 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Health Technology Assessment programme	Ipilimumab for previously untreated unresectable malignant melanoma: a single technology appraisal
2014	NIHR Health Services and Delivery Research programme	The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST).
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Breast reduction surgery for hypermastia: clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-35 (dabrafenib)]
2014	NIHR Health Services and Delivery Research programme	Geographical and temporal understanding in place of death in England (1984–2010): analysis of trends and associated factors to improve end-of-life care (GUIDE_Care) – primary research
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Magnetic Resonance Imaging (MRI) for small bowel and pelvis in Crohn disease
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Arthroscopy of the knee joint for gonarthrosis]
2014	NIHR Health Services and Delivery Research programme	What evidence is there for a relationship between organisational features and patient outcomes in congenital heart disease services? A rapid review
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Intensive Care Medicine consultation items
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palliation vs. curation - an attempt to clarify terms]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Azacitidine (Vidaza) for acute myeloid leukaemia – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents: a review of the effectiveness, safety, and guidelines
2014	Medical Services Advisory Committee (MSAC)	Palliative care consultation items
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
2014	National Institute for Health and Care Excellence (NICE)	Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers. NICE medical technologies guidance 20
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ecorafenib and binimetinib for BRAF V600 mutation-positive melanoma – first and second line
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Neonatal screening for biotinidase deficiency]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Respiratory precautions for protection from bioaerosols or infectious agents: a review of the clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Review of interim funded service: breast Magnetic Resonance Imaging (MRI)
2014	Haute Autorite de sante (HAS)	[Hip implants]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ibrutinib (Imbruvica) for newly diagnosed chronic lymphocytic leukaemia – first line
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Comparative effectiveness research of computer-assisted navigation in knee arthroplasty]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Motor interventions for autism spectrum disorder in children: clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	IncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Niraparib for HER2-negative, germline BRCA mutated, locally advanced or metastatic breast cancer – first or second line
2014	Andalusian Health Technology Assessment Area (AETSA)	[Genetic diseases in Spain: map of genetic tests available in the national health system]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence
2014	Medical Services Advisory Committee (MSAC)	RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients.
2014	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Development of composite indicators to measure the quality of prevention and chronic management activities for gynecological cancer screening in primary care]
2014	Haute Autorite de sante (HAS)	[Endobronchial ultrasound-guided transbronchial needle aspiration]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Cositecan (Karenitecin) for advanced mucinous epithelial ovarian cancer – second line
2014	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness, safety and efficiency of palivizumab for prevention of respiratory syncytial virus infection in premature infants]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Oral ginger for the management of chemotherapy-induced nausea and vomiting in pediatric patients: clinical effectiveness and safety
2014	Medical Services Advisory Committee (MSAC)	Resubmission Cetuximab and RAS testing under MBS 73330
2014	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[EndoBarrier® evaluation device for the treatment of morbid obesity with or without diabetes mellitus type II]
2014	Haute Autorite de sante (HAS)	[Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia)]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Macitentan - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Mogamulizumab for adult T-cell leukaemia/lymphoma – second and subsequent line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term use of bevacizumab for the treatment of age-related macular degeneration: safety
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Turoctocog alfa - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Neratinib for HER2-positive early breast cancer
2014	Norwegian Knowledge Centre for the Health Services (NOKC)	[End-of-life care - how to find the appropriate level and intensity of medical treatment of seriously ill and dying patients]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Methylene blue for the prevention and treatment of ifosfamide-induced encephalopathy: clinical effectiveness and safety
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Blood count and coagulation testing before renal biopsy
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Niraparib for high grade serous, platinum sensitive ovarian cancer – second line maintenance therapy
2014	Agency for Healthcare Research and Quality (AHRQ)	Negative pressure wound therapy technologies for chronic wound care in the home setting
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nasogastric feeding tubes versus percutaneous endoscopic gastrostomy for patients with head or neck cancer: a review of clinical effectiveness and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Special report: medication adherence
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Separate instrument sets for prevention of tumor seeding during tumor resection and flap surgery
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2014	Agency for Healthcare Research and Quality (AHRQ)	Behavioral sexual risk reduction counseling in primary care to prevent sexually transmitted infections: an updated systematic evidence review for the U.S. Preventive Services Task Force
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Thrombophilia testing for women who have had pregnancy loss: clinical evidence, cost-effectiveness, and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Bronchial thermoplasty for treatment of inadequately controlled severe asthma
2014	Health Information and Quality Authority (HIQA)	Health technology assessment (HTA) of public access defibrillation
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	NIHR Health Technology Assessment programme	Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
2014	Blue Cross Blue Shield Association (BCBS)	CYP2D6 pharmacogenomics of tamoxifen treatment
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Psychosocial interventions for patients with sickle cell disease
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) for recurrent or persistent stage IVB cervical cancer – in combination with chemotherapy
2014	Agency for Healthcare Research and Quality (AHRQ)	Screening for gonorrhea and chlamydia: systematic review to update the U.S. Preventive Services Task Force Recommendations
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bone marrow aspiration or biopsy for patients with immune thrombocytopenia: clinical evidence
2014	Blue Cross Blue Shield Association (BCBS)	Endovascular treatments for acute ischemic stroke in adults
2014	Haute Autorite de sante (HAS)	[Detection of enterovirus genome in cerebrospinal fluid by gene amplification in meningitis patients]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benefit assessment of an HPV test in primary screening for cervical cancer - Rapid report]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Observation care and the two midnight rule: current perspectives and publications (2013-2014)
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Cologuard® for colorectal cancer screening
2014	Agency for Healthcare Research and Quality (AHRQ)	Medication therapy management interventions in outpatient settings
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Patient-controlled analgesia for acute injury transfers: a review of the clinical effectiveness, safety, and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Cost-effectiveness studies of new hepatitis C treatments
2014	Haute Autorite de sante (HAS)	[Assessment of the risks associated with aesthetic mesotherapy practices]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Docusate for treatment of constipation
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Terahertz intraoperative breast cancer probe
2014	Agency for Healthcare Research and Quality (AHRQ)	Imaging techniques for the diagnosis and staging of hepatocellular carcinoma
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety
2014	Haute Autorite de sante (HAS)	[Elements to evaluate for managing a patient in outpatient surgery]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "breast cancer"]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Intravenous insulin infusion: the evidence for safe nursing administration practice
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Betrixaban for the prevention of venous thromboembolism – first line
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal cancer
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hand sanitizers for the prevention of infection transmission: comparative clinical effectiveness and clinical evidence
2014	University of York	Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Aspirin for VTE prophylaxis in hip and knee replacement surgery
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Cydar imaging overlay system for endovascular surgery
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cardiopulmonary resuscitation for elderly adults in chronic or long-term care: clinical effectiveness and guidelines
2014	University of York	Effects of lay-led self-care education programmes
2014	Haute Autorite de sante (HAS)	[Assessment of non-invasive methods for measuring liver fibrosis in chronic hepatitis B. Initial assessment and follow-up of non-treated adult patients]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-05 (sofosbuvir)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Association of lumen number and diameter with complications in peripherally-inserted central catheters